December 2002
Volume 43, Issue 13
ARVO Annual Meeting Abstract  |   December 2002
INTACSTM for Keratoconus
Author Affiliations & Notes
  • M Fuhrman
    Ophthalmology Mount Sinai School of Medicine New York NY
  • SA Haji
    New York NY
  • IJ Dualan
    New York NY
  • PA Asbell
    New York NY
  • Footnotes
    Commercial Relationships   M. Fuhrman, None; S.A. Haji, Addition Technology, Inc F; I.J. Dualan, Addition Technology, Inc F; P.A. Asbell, Addition Technology, Inc F. Grant Identification: Supported in part by NEI#01867,Research to Prevent Blindness,Inc.& Addition Technology,Inc
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 3236. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M Fuhrman, SA Haji, IJ Dualan, PA Asbell; INTACSTM for Keratoconus . Invest. Ophthalmol. Vis. Sci. 2002;43(13):3236.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: INTACSTM are implants placed in the peripheral stroma to flatten the central cornea and are FDA approved to correct myopia. We reported the use of INTACSTM to treat patients with keratoconus, as an alternative to contact lenses or transplant surgery. Methods: Patients diagnosed with keratoconus by clinical exam, keratometry and topography, who had poor VA with spectacles and were contact lens intolerant, underwent INTACSTM placement (sizes 0.25, 0.30mm or 0.35mm). In eight eyes, complete preop and postop exams were performed and uncorrected visual acuity (UCVA), best spectacle corrected visual acuity (BSCVA), K readings, topography, asphericity(Q value) and predicted corneal acuity (PCA) were correlated. Results: Eyes with at least 3 month postop data available showed: UCVA improvement of 2-8 lines, BSCVA change of 0 to 8 lines improvement, no loss of BSCVA, no intra-operative adverse events, average K flattening of 0 to 6 D, average asphericity(Q value) change of -1.50 (increased prolate) and an average PCA of 20/40. Clinically all patients noted improved visual function. Conclusion: INTACSTMcan alter the corneal curvature in keratoconus and can be placed without complications. Improved clinical function and corneal measurements are noted, but the degree of change is not predictable. Further evaluation will be needed to determine which keratoconus eyes will respond best to INTACSTM placement.

Keywords: 450 keratoconus 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.